Table 1.
Comparison of clinical data between study groups. BMI—body mass index, NSAID—non-steroidal anti-inflammatory drugs. Green: p adj. < 0.1.
| AMI Control | AMI Post-COVID | Control | Control Post-COVID |
p adj. AMI Control vs. AMI Post-COVID |
p adj. AMI Control vs. Control |
p adj. AMI Post-COVID vs. Control Post-COVID |
p adj. AMI Post-COVID vs. Control |
|
|---|---|---|---|---|---|---|---|---|
| Male sex, n (%) | 22, (73%) | 44, (84%) | 27, (37%) | 31, (26%) | 1 | 1 | <0.01 | 0.01 |
| Age, years Med [Q1; Q3] |
65.5 [56.25; 71.5] |
59 [50.75; 72] |
48 [43.5; 54.5] |
49 [47; 55.5] |
0.29 | <0.01 | <0.01 | <0.01 |
| BMI Med [Q1; Q3] |
27.91 [24.9; 30.83] |
26.73 [24.39; 30.9] |
24.38 [23.13; 26.73] |
26.4 [22.87; 29.66] |
0.82 | 0.05 | 0.55 | 0.04 |
| Smoking, n (%) | 18, (44%) | 37, (65%) | 25, (16%) | 31, (23%) | 1 | 1 | 0.09 | 0.03 |
| Arterial hypertension, n (%) | 22, (100%) | 44, (86%) | 25, (32%) | 31, (32%) | 1 | <0.01 | <0.01 | <0.01 |
| Diabetes mellitus, n, (%) | 22, (27%) | 44, (16%) | 25, (0%) | 31, (0%) | 1 | 0.96 | 1 | 1 |
| History of MI, n (%) | 22, (23%) | 44, (14%) | 25, (0%) | 31, (0%) | 1 | 1 | 1 | 1 |
| Chronic obstructive pulmonary disease, n (%) | 22, (5%) | 44, (2%) | 25, (0%) | 31, (0%) | 1 | 1 | 1 | 1 |
| Chronic kidney disease, n (%) | 22, (9%) | 43, (7%) | 25, (0%) | 31, (3%) | 1 | 1 | 1 | 1 |
| History of PCI, n (%) | 22, (18%) | 44, (9%) | 25, (0%) | 31, (0%) | 1 | 1 | 1 | 1 |
| Antiplatelet drugs, n (%) | 22, (23%) | 41, (17%) | 25 *, (12%) | 31 *, (3%) | 1 | 1 | 1 | 1 |
| Statins, n (%) | 22, (27%) | 41, (7%) | 25, (20%) | 31, (3%) | 1 | 1 | 1 | 1 |
| ACE inhibitors/AT-II blockers, n (%) | 21, (62%) | 40, (30%) | 25, (20%) | 31, (16%) | 1 | 0.84 | 1 | 1 |
| NSAIDs | 19, (0%) | 40, (0%) | 27, (0%) | 31, (0%) | 1 | 1 | 1 | 1 |
| SARS-CoV-2 Vaccination, n (%) | 22, (55%) | 43, (53%) | 27, (63%) | 31, (81%) | 1 | 1 | 1 | 1 |
| History of bleeding, n (%) | 22, (5%) | 43, (9%) | 25, (4%) | 31, (0%) | 1 | 1 | 1 | 1 |
* All antiplatelet drugs were canceled the week before the inclusion in the control groups (see exclusion criteria).